Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NDI-219216
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nimbus Starts First Human Trial of WRN Inhibitor NDI-219216 for MSI-H Tumors
Details : NDI-219216 is a highly potent and selective non-covalent investigational inhibitor of Werner syndrome helicase (WRN) activity being developed for the treatment of neoplasms.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2025
Lead Product(s) : NDI-219216
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Eli Lilly
Deal Size : $496.0 million
Deal Type : Collaboration
Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
Details : Nimbus, in collaboration with Eli Lilly, has achieved a milestone by targeting a specific isoform of AMP-activated protein kinase (AMPK) for the treatment of cardiometabolic diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 25, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Eli Lilly
Deal Size : $496.0 million
Deal Type : Collaboration
Lead Product(s) : NDI-101150
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline
Details : NDI-101150, a small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) which is under phase 1/2 clinical development for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2024
Lead Product(s) : NDI-101150
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Recipient : Anagenex
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Anagenex and Nimbus will discover small molecule drugs for multiple challenging targets by applying Anagenex’s AI driven parallel biochemistry platform to generate experimentally measured datapoints for each of Nimbus’ nomina...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Recipient : Anagenex
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : NDI-034858
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : $6,000.0 million
Deal Type : Agreement
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
Details : Following the completion of this transaction, Takeda has now acquired TAK-279, formerly known at Nimbus as NDI-034858. This acquisition strengthens Takeda’s growing late-stage pipeline and potentially expands its portfolio and patient impact across mul...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $4,000.0 million
August 02, 2023
Lead Product(s) : NDI-034858
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : $6,000.0 million
Deal Type : Agreement
Lead Product(s) : NDI-101150
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Google Ventures
Deal Size : $210.0 million
Deal Type : Private Placement
Details : Nimbus will use financing to continue the ongoing clinical development of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with solid tumors.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 09, 2023
Lead Product(s) : NDI-101150
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Google Ventures
Deal Size : $210.0 million
Deal Type : Private Placement
Lead Product(s) : NDI-034858
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : $6,000.0 million
Deal Type : Acquisition
Details : The acquisition strengthens Takeda's autoimmune portfolio, preferably NDI-034858 candidate, an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases, especilally moderate to severe plaque psoriasis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $4,000.0 million
December 13, 2022
Lead Product(s) : NDI-034858
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : $6,000.0 million
Deal Type : Acquisition
Lead Product(s) : NDI-034858
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NDI-034858 is an allosteric TYK2 inhibitor developed by Nimbus Therapeutics that is being evaluated for the treatment of multiple autoimmune diseases. In preclinical studies, NDI-034858 has demonstrated exceptional functional selectivity and wide therape...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : NDI-034858
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Eli Lilly
Deal Size : $496.0 million
Deal Type : Collaboration
Details : Nimbus’s computational drug discovery engine and expertise in structure-based drug design, Nimbus is uniquely positioned to develop isoform-selective small molecule activators of AMPK with potential therapeutic application to a broad range of metabolic...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Eli Lilly
Deal Size : $496.0 million
Deal Type : Collaboration
Lead Product(s) : NDI-034858
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In a Phase 1 clinical study, NDI-034858 demonstrated a good tolerability profile and evidence of clinical and pharmacodynamic activity across multiple measures of disease pathology in psoriasis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2022
Lead Product(s) : NDI-034858
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable